ERAS

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Erasca received FDA Fast Track designation for the Pan-RAS molecular glue ERAS-0015 in patients with metastatic pancreatic adenocarcinomaAug 24, 2026
• Erasca reported updated Phase 1 data and outlined registration-enabling plans for ERAS-0015 in KRAS-mutant solid tumorsJul 14, 2026
• Erasca receives a U.S. patent covering its pan-KRAS inhibitor ERAS-4001Feb 24, 2026
• Erasca announces issuance of a U.S. patent covering pan-RAS molecular glue ERAS-0015Nov 6, 2025
• Erasca announces IND clearance for ERAS-4001, a potential first-in-class pan-KRAS inhibitorJun 2, 2025